Artificial Intelligence | Machine Learning | Machine Perception Immunai | Decoding the Immune System to Improve Health


Consumer, Immunology, Healthcare, Biotechnology, Genomic Technologies New York, NY, United States

Immunai

Artificial Intelligence | Machine Learning | Machine Perception


Immunai | Decoding the Immune System to Improve Health

Immunai

Immunology, Healthcare, Biotechnology, Genomic Technologies


New York, NY, United States

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes

Immunai’s end-to-end single-cell platform enables high resolution profiling of the immune system at industrial scale, generating biological insights that accelerate R&D and power novel discoveries

 

B2C, B2B

26 to 50

Seed

$20,000,000

Launched

2019

 
 

Healthcare
Health Care Facilities & Hospitals
Biotechnology

Decoding the Immune System to Improve Health

N/A

 
 

Analytics
Service

Yes

Active

 
 

   Machine Learning
   Machine Perception
   Natural Language Processing


Immunai?s immune Profiling Platform

Immunai?s immune Profiling Platform


N/A

 

   Software


NA

NA


NA

NA

 
 

3

1

$215M

Company was founded 2019 and it took almost 2 years (Oct 2021) to raise first external round

 
 

Date

Round

$ Raised

Investors

10/28/2021

Series B

$215M

8VC, Icon Ventures, Piedmont Capital

Date : 10/28/2021

Round: Series B

$ Raised: $215M

Investors: 8VC, Icon Ventures, Piedmont Capital

 

Investors

Interested in researching Immunai?

We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Immunai

Get Started - Deal Souring Platform

 
Noam Solomon


Noam Solomon
CEO

Daniel Wells


Daniel Wells
Co-Founder

 
 

Potential Customers

Interested in what they do or partnership?

Learn more about how they work

Schedule a Call w/ Immunai